Late additionStrategic
Gilead Sciences acquires Tubulis
up to $5bnPurchase price according to the source
SourcingClub was not involved in this transaction.
Gilead Sciences acquires the German biotech company Tubulis for up to $5bn, of which $3.15bn in cash and up to $1.85bn in milestone payments. Tubulis develops cancer drugs based on antibody-drug conjugates and is to continue at Gilead as its own ADC research unit.
In context
In June 2026 it is the 2nd of 2 deals in Healthcare on the Deal-Radar.
Deal-Radar editorial team · responsible: Nick Herbig
late addition, source dated 19 Jun 2026: eqtgroup.com
Who was involved.
- Buyer
- Gilead Sciences
- Target
- Tubulis
- Seller
- Gesellschafter, darunter EQT Life Sciences
- Type
- Strategic
- Sector
- Healthcare & Medtech
- Country
Germany
- Source dated
- 19/06/2026
- Purchase price
- up to $5bn, according to the source
- Source
- eqtgroup.com
Deal-Radar no. 47-215 · added in Week 47/2026, first reported on 19/06/2026 · publicly reported, no guarantee · SourcingClub was not involved in this transaction. Report an error · Sources and limits
We report publicly announced information and link the source; we accept no liability for its accuracy. No offer and no investment, legal or tax advice. The operators of linked pages are responsible for their content. We correct errors as soon as we learn of them. The context is based only on deals recorded in the Deal-Radar and is not complete.
Valuation in this industry.
5.9 to 10.0times EBITDA
- 5.9x to 7.6xRevenue under €5m
- 7.0x to 9.0x€5m to €50m
- 8.2x to 10.0xover €50m
Market range for Healthcare & Medical Technology, not the price of this deal. Data basis: DUB KMU-Multiples, Q3/2026; preparation: SourcingClub.
Multiples by size class for Healthcare & Medical Technology 62 deals in this industry on the radar
June 2026 on the Deal-Radar.
4 of 21 deals were of the type Strategic.
- Buy-out8
- Add-on4
- Secondary4
- Strategic4
- Carve-out1
Strategic and succession in Week 47/2026.
All deals in June 2026New deals every day. By email on Mondays.
All deals of the previous week in one email, with source and adviser.
